

From the New England Society for Vascular Surgery

# In-hospital versus postdischarge adverse events following carotid endarterectomy

Margriet Fokkema, MD,<sup>a,b</sup> Rodney P. Bensley, MD,<sup>a</sup> Ruby C. Lo, MD,<sup>a</sup> Allan D. Hamden, MD,<sup>a</sup> Mark C. Wyers, MD,<sup>a</sup> Frans L. Moll, MD, PhD,<sup>b</sup> Gert Jan de Borst, MD, PhD,<sup>b</sup> and Marc L. Schermerhorn, MD,<sup>a</sup> *Boston, Mass; and Utrecht, The Netherlands*

**Objective:** Most studies based on state and nationwide registries evaluating perioperative outcome after carotid endarterectomy (CEA) rely on hospital discharge data only. Therefore, the true 30-day complication risk after carotid revascularization may be underestimated.

**Methods:** We used the National Surgical Quality Improvement Program database 2005-2010 to assess the in-hospital and postdischarge rate of any stroke, death, cardiac event (new Q-wave myocardial infarction or cardiac arrest), and combined stroke/death and combined adverse outcome (S/D/CE) at 30 days following CEA. Multivariable analyses were used to identify predictors for in-hospital and postdischarge events separately, and in particular, those that predict postdischarge events distinctly.

**Results:** A total of 35,916 patients who underwent CEA during 2005-2010 were identified in the National Surgical Quality Improvement Program database; 59% were male, median age was 72 years, and 44% had a previous neurologic event. Thirty-day stroke rate was 1.6% (n = 591), death rate was 0.8% (n = 272), cardiac event rate was 1.0% (n = 350), stroke or death rate was 2.2% (n = 794), and combined S/D/CE rate was 2.9% (n = 1043); 33% of strokes, 53% of deaths, 32% of cardiac events, 40% of combined stroke/death, and 38% of combined S/D/CE took place after hospital discharge. Patients with a prior stroke or transient ischemic attack had similar proportions of postdischarge events compared with patients without prior symptoms. Independent predictors for postdischarge events, but not for in-hospital events were female sex (stroke [odds ratio (OR), 1.6; 95% confidence interval (CI), 1.2-2.1] and stroke/death [OR, 1.4; 95% CI, 1.1-1.7]), renal failure (stroke [OR, 3.0; 95% CI, 1.4-6.2]) and chronic obstructive pulmonary disease (death [OR, 2.5; 95% CI, 1.6-3.7], stroke/death [OR, 1.8; 95% CI, 1.4-2.4], and S/D/CE [OR 1.8, 95% CI 1.4-2.3]).

**Conclusions:** With 38% of perioperative adverse events after CEA happening posthospitalization, regardless of symptoms status, we need to be alert to the ongoing risks after discharge particularly in women, patients with renal failure, or chronic obstructive pulmonary disease. This emphasizes the need for reporting and comparing 30-day adverse event rates when evaluating outcomes for CEA, or comparing carotid stenting to CEA. (*J Vasc Surg* 2013;57:1568-75.)

The benefit of carotid endarterectomy (CEA) and carotid angioplasty and stenting (CAS) is highly influenced by the rate of perioperative adverse events, defined as stroke, myocardial infarction (MI), or mortality up to 30 days after the procedure. Many studies reporting and comparing perioperative complication rates following carotid revascularization rely on state and nation-wide registries, which only include in-hospital data.<sup>1-3</sup> However, procedure-related complications and mortality after

revascularization procedures might also take place after hospital discharge. Results from the Society for Vascular Surgery Vascular Registry suggest that in-hospital events do not reflect the full procedural event rate after CAS and CEA, as an additional 31% and 22% of combined adverse events, respectively, occurred after discharge from the hospital.<sup>4</sup> However, in that analysis, less than 50% of the total patients completed 30-day follow-up, and thus, these estimates may under- or overestimate the true event rates. Others have suggested that 10% to 37% of strokes took place after discharge, but these studies are limited by small study size or incomplete follow-up.<sup>5,6</sup> Also, these analyses did not include adverse outcomes after CEA other than stroke. To compare and evaluate outcomes of CEA and CAS, it seems crucial to report 30-day outcome. For patients, it is important to understand the true operative risk they are facing when deciding whether to undergo CEA. Those patients who are at high risk to develop procedural-related events after discharge might benefit from closer surveillance after discharge and possibly changes in management. Different preoperative patient characteristics may be related to the timing of events. Our objective was to assess the in-hospital and postdischarge rate of adverse events following CEA in a 100% follow-up cohort at 30 days and to identify independent predictors for the timing of these events.

From the Department of Vascular Surgery, Beth Israel Deaconess Medical Center, Boston<sup>a</sup>; and the Department of Vascular Surgery, University Medical Center Utrecht, Utrecht.<sup>b</sup>

This work was supported by the NIH T32 Harvard-Longwood Research Training in Vascular Surgery grant HL007734.

Author conflict of interest: Dr Schermerhorn is a consultant for Endologix, Medtronic, and Boston Scientific.

Presented at the Thirty-ninth Annual Meeting of the New England Society for Vascular Surgery, Boston, Mass, September 21-23, 2012.

Additional material for this article may be found online at [www.jvascsurg.org](http://www.jvascsurg.org).  
Reprint requests: Marc L. Schermerhorn, MD, Department of Vascular Surgery, Beth Israel Deaconess Medical Center, 110 Francis St, Ste 5B, Boston, MA 02215 (e-mail: [mscherm@bidmc.harvard.edu](mailto:mscherm@bidmc.harvard.edu)).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214/\$36.00

Copyright © 2013 by the Society for Vascular Surgery.

<http://dx.doi.org/10.1016/j.jvs.2012.11.072>

## METHODS

**Database.** Data were obtained from medical records of patients undergoing CEA between 2005 and 2010 in the American College of Surgeon's National Surgical Quality Improvement Program (NSQIP) database. The NSQIP is a multicenter, prospective quality-improvement registry that includes academic and private US hospitals. In 2005, 37 institutions participated in the program, and the number has increased to 258 by 2010. Demographics, preoperative risk factors, intraoperative variables, and 30-day postoperative mortality and morbidity outcomes are collected, validated, and submitted by a trained and audited surgical clinical nurse-reviewer designated by the American College of Surgeon. No specific procedural information on CEA (such as reconstruction technique, shunt use, type of artery closure, or neurologic monitoring) is captured by the current iteration of NSQIP. Postsurgical data are obtained for the entire 30-day time period, regardless of whether the patient is discharged to the outpatient setting before this time. A detailed description of the NSQIP study methods has been previously published and validated.<sup>7</sup> The NSQIP data are subject to annual auditing, and the reliability of accurate data acquisition has improved with each year.<sup>8</sup>

**Patient selection.** The NSQIP database was queried to identify patients undergoing CEA between 2005 and 2010 using the Current Procedural Terminology codes 35301 and 35390. Cases were selected in which CEA was the primary procedure. Patients undergoing concurrent cardiac surgery were excluded. The remaining procedure data were searched to ensure that no other major procedure was included. Indication for surgery (symptom status and degree of stenosis) is not available in the database. Therefore, we were not able to formally stratify patients by symptom status. However, NSQIP captures a history of a previous neurologic event (stroke, transient ischemic attack [TIA]) and hemiplegia, without the timing and laterality of these events. This variable was used to distinguish patients who were clearly asymptomatic (ASX) from those who had previous neurologic symptoms (SXS). Recent work from our group showed that those with prior SXS were most likely to be symptomatic.<sup>9</sup>

**Endpoints and measurements.** Our primary endpoint was the development of stroke, death, or a cardiac event within 30 days after CEA. Stroke was defined as the development of an embolic, thrombotic, or hemorrhagic vascular accident or stroke with motor, sensory, or cognitive dysfunction (eg, hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory) that persists for 24 or more hours. A cardiac event was defined as a new Q-wave MI on electrocardiogram or cardiac arrest that necessitated cardiopulmonary resuscitation. Our secondary endpoint was wound infection, defined as either involving the carotid artery, deep (involving deep soft tissue's eg, fascia and muscle layers of the incision) or a superficial surgical site infection (limited to skin and subcutaneous).

Results were stratified for the in-hospital period (intraoperative or predischarge) and the postdischarge period through 30-days after surgery. Timing to adverse event was recorded per day, starting from the day of surgery (day 0). The proportion of postdischarge events was analyzed for both patients with a history of neurologic symptoms and patients without a history of neurologic symptoms. For in-hospital analysis, patients with postdischarge events were excluded. Likewise, for postdischarge events, patients with in-hospital events were excluded. If patients suffered both in-hospital and postdischarge events, the in-hospital event was counted for analysis. Predictor variables for the primary outcome included demographics and preoperative variables. Continuous variables were categorized for the purpose of this study. Detailed definitions of these variables are listed in the [Appendix](#) (online only).

**Statistical analysis.** Bivariate analysis was carried out to assess the relation of the preoperative variables with the primary outcome (stroke, death, cardiac event or a composite of stroke/death and S/D/CE) at the different time points (in-hospital, postdischarge, 30-day) using Pearson  $\chi^2$  test and Fisher exact test. Initial bivariate analysis included 29 preoperative demographic and comorbidity variables. Multivariable logistic regression was used to assess independent risk factors for outcome events at each of the above specified time points. Demographics and preoperative variables were entered into the multivariable regression analysis if  $P < .2$  in bivariate analysis. Associations were calculated using backward elimination procedure, in which all variables were entered in the first step and removed stepwise based on the highest nonsignificant  $P$  value ( $P \geq .05$ ). After carrying out this iterative process, covariates were included in the final model if predictive of primary outcome events in any of the three specified clinical time intervals with this model demonstrating the contribution of each covariate to timing of events. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Hosmer and Lemeshow test was used to test the goodness of fit in each model. Statistical analysis was performed using SPSS v. 19.0 statistical software (SPSS Inc, Chicago, Ill).

## RESULTS

A total of 35,916 patients undergoing CEA between 2005 and 2010 in the NSQIP database were identified and included for analysis. The median age was 72 years (interquartile range [IQR], 13), 59.1% were men, and 44.1% had a history of stroke, TIA, or hemiplegia. Demographics, clinical characteristics, and operative details are shown in Table I.

Stroke rate at 30 days was 1.6% ( $n = 591$ ; prior neurologic SXS 2.4% vs ASX 1.1%; OR, 2.25; 95% CI, 1.89-2.66;  $P < .001$ ), death rate was 0.8% ( $n = 272$ ; prior neurologic SXS 1.1% vs ASX 0.5%; OR, 2.03; 95% CI, 1.59-2.59;  $P < .001$ ), and cardiac event rate was 1.0% ( $n = 350$ ; prior neurologic SXS 1.1% vs ASX 0.8%; OR, 1.38; 95% CI, 1.12-1.70;  $P = .003$ ). Combined stroke/death

**Table I.** Demographics and clinical characteristics of 35,916 patients undergoing carotid endarterectomy (CEA)

Variable	No. or median	% or (IQR)
<b>Demographics</b>		
Age, years	72	(13)
<60 years	5123	14.4
60-69 years	11,283	31.8
70-80 years	13,226	37.3
>80 years	5871	16.5
<b>Sex</b>		
Male	21,184	59.1
Female	14,657	40.9
Race, non-white	3046	8.5
<b>Clinical characteristics</b>		
Redo CEA	82	0.2
Hx stroke/hemiplegia	8936	24.9
Hx of TIA	9954	27.7
Hx of angina or MI	1364	3.8
Congestive heart failure	371	1.0
Previous PCI	6710	18.7
Previous cardiac surgery	8196	22.8
Diabetes mellitus	9984	27.8
Hypertension	30,658	85.4
Current smoker	10,033	27.9
<b>Hx of smoking</b>		
<10 pack-years	11,161	32.3
10-29 pack-years	4939	13.8
30-49 pack-years	3726	10.4
50-70 pack-years	3517	9.8
>70 pack-years	2921	8.1
Alcohol use >2 drinks/day	1557	4.3
<b>BMI</b>		
<18.5	537	1.5
18.5-24.9	9507	26.5
25-29.9	13,814	38.5
30-34.9	7470	20.8
35-40	2687	7.5
≥40	1154	3.2
<b>Height</b>		
<64 inch	12,040	34.0
64-70 inch	14,750	41.6
>70 inch	8636	24.4
Renal failure	476	1.3
Hx of COPD	3792	10.6
Dyspnea	6847	19.1
Steroid use	747	2.1
Hx of revascularization for PVD	3499	9.7
Rest pain/gangrene	344	1.0
<b>Functional status</b>		
Independent	33,952	94.5
Dependent	1961	5.5
Emergency procedure	614	1.7
ASA class >3	4753	13.2
General anesthesia	30,184	84.1
Vascular surgeon	34,019	94.7
PGY level ≤3	4152	11.6

ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Hx, history; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; PGY, postgraduate year of resident; PVD, peripheral vascular disease; TIA, transient ischemic attack.

rate was 2.2% (n = 794; prior neurologic SXS 3.1% vs ASX 1.5%; OR, 2.16; 95% CI, 1.87-2.50;  $P < .001$ ) and combined S/D/CE rate was 2.9% (n = 1043; prior neurologic

SXS 3.9% vs ASX 2.1%; OR, 1.86; 95% CI, 1.64-2.11;  $P < .001$ ). The median length of hospital stay was 1 day (IQR, 1).

**Timing of events.** In-hospital S/D/CE occurred in 656 patients (1.8%). After discharge, an additional 38% of S/D/CE (n = 399; 1.1%) occurred; 33% of strokes (n = 195; 0.5%), 53% of deaths (n = 144; 0.4%), 32% of cardiac events (n = 122; 0.3%), and 40% of stroke/death (n = 320; 0.9%) occurred after discharge. The proportion of combined S/D/CE after discharge was similar in patients with prior neurologic symptoms vs those without (39% and 38%, respectively). Postdischarge, stroke happened in 34% of patients with prior neurologic symptoms, and in 32% of ASX patients; 52% of deaths, 31% of cardiac events, and 40% of stroke/death occurred after discharge in patients with prior neurologic symptoms, vs 55% of deaths, 33% of cardiac events, and 40% of stroke/death in ASX patients (Table II). In-hospital adverse events happened at a median of 1 day (IQR, 1). These patients were discharged from the hospital at a median of 7 days (IQR, 8) postoperatively. Patients who experienced postdischarge events were discharged at day 1 (median) postoperatively (IQR, 1). Postdischarge stroke occurred at a median of 8 days after the operation (IQR, 11) (Fig). MI or cardiac arrest (cardiac events) after discharge took place at a median of 6 days (IQR, 17) and 11 days (IQR, 19), respectively. Patients who survived to discharge but did not survive the postdischarge period, died at a median interval of 11 days (IQR, 15).

Thirty-day wound infection rate was 0.5% (n = 197). The majority of wound infections took place after discharge: 94% of superficial wound infection (n = 141; 0.4%), 94% of deep wound infection (n = 47; 0.1%) and 89% of carotid infection (n = 9; 0.03%).

### Predictors for stroke

**In-hospital.** Independent predictors for in-hospital stroke were redo CEA, a history of stroke/hemiplegia, history of TIA, history of angina/MI, underweight (vs normal weight) and obesity class II (vs normal weight), functional dependent status (vs independent), emergency procedures, and ASA class >3 (Table III).

**Postdischarge.** History of stroke/hemiplegia, history of TIA, renal failure, and female sex were associated with increased risk of postdischarge stroke on multivariable analyses (Table III). Women were more likely to have a postdischarge stroke than men (38.1% vs 29.0%; OR, 1.57; 95% CI, 1.18-2.09;  $P = .002$ ). In patients with a previous neurologic event, a significantly higher stroke rate was seen in women compared with men (1.0% vs 0.7%; OR, 1.5; 95% CI, 1.1-2.1;  $P = .02$ ). In ASX patients, the stroke rate was again higher in women with a similar OR, however, this did not reach statistical significance (0.4% vs 0.3%; OR, 1.6; 95% CI, 0.97-2.5;  $P = .08$ ). Stroke in woman took place at a median of 2 days (IQR, 6), compared with 1 day (IQR, 6) in men ( $P = .4$ ). Stroke in patients with renal failure took place at a median of 7 days (IQR, 9) after discharge, compared with 1 day (IQR, 6) in patients without renal failure ( $P < .001$ ). Female gender and renal

**Table II.** Outcome and timing of in-hospital, postdischarge, and 30-day events of 35,916 patients undergoing carotid endarterectomy (CEA)


	<i>Time to event, days</i>		<i>In-hospital event rate, No. (%)</i>	<i>Postdischarge event rate, No. (%)</i>	<i>30-day event rate, No. (%)</i>	<i>Proportion of events that occurred after discharge</i>
	<i>Median, IQR</i>	<i>Mean ± SD</i>				
All patients						
Stroke	1, 6	4.5 ± 6.6	396 (1.1)	195 (0.5)	591 (1.6)	<b>33%</b>
Death	8.5, 14	11.2 ± 8.6	128 (0.4)	144 (0.4)	272 (0.8)	<b>53%</b>
Cardiac event	NA	NA	238 (0.7)	112 (0.3)	350 (1.0)	<b>32%</b>
Stroke/death	NA	NA	480 (1.3)	320 (0.9) <sup>a</sup>	794 (2.2)	<b>40%</b>
Stroke/death/ cardiac event	NA	NA	656 (1.8)	399 (1.1) <sup>b</sup>	1043 (2.9)	<b>38%</b>
Patients with a prior neurologic event						
Stroke	2, 6	4.6 ± 6.4	249 (1.6)	127 (0.8)	376 (2.4)	<b>34%</b>
Death	9, 15	11.8 ± 8.7	81 (0.5)	86 (0.5)	167 (1.1)	<b>52%</b>
Cardiac event	NA	NA	126 (0.8)	56 (0.4)	182 (1.1)	<b>31%</b>
Stroke/death	NA	NA	302 (1.9)	201 (1.3)	497 (3.1)	<b>40%</b>
Stroke/death/ cardiac event	NA	NA	387 (2.4)	238 (1.5)	616 (3.9)	<b>39%</b>
Asymptomatic patients						
Stroke	1, 6	4.5 ± 6.9	147 (0.7)	68 (0.3)	215 (1.1)	<b>32%</b>
Death	8, 8	10.5 ± 8.2	47 (0.2)	58 (0.3)	105 (0.5)	<b>55%</b>
Cardiac event	NA	NA	112 (0.6)	56 (0.3)	168 (0.8)	<b>33%</b>
Stroke/death	NA	NA	178 (0.9)	119 (0.6)	297 (1.5)	<b>40%</b>
Stroke/death/ cardiac event	NA	NA	269 (1.3)	161 (0.8)	427 (2.1)	<b>38%</b>

IQR, Interquartile range; NA, data not available; SD, standard deviation.

Bold values indicate  $P < .05$ .

<sup>a</sup>Six patients died postdischarge after having an in-hospital stroke.

<sup>b</sup>Twelve patients experienced a secondary postdischarge event, after having an in-hospital stroke (N = 6) or cardiac event (N = 6).



**Fig.** Days from operation until postdischarge stroke after carotid endarterectomy (CEA). Median days, 8; interquartile range [IQR], 11.

failure were both predictive for postdischarge stroke in multivariable analysis, but not for in-hospital stroke (Table III).

**Predictors for stroke or death**

**In-hospital.** In multivariable analysis, age >80 years, history of stroke/hemiplegia, history of TIA, history of angina/MI, renal failure, history of revascularization for peripheral vascular disease (PVD), dependent functional status, emergency procedures, and ASA class >3 were independent predictors for stroke or death (Table IV).

**Postdischarge.** Female sex, history of stroke/hemiplegia, history of angina/MI, renal failure, chronic obstructive pulmonary disease (COPD) and dependent functional status were independently associated with postdischarge stroke or death. Female sex and COPD were predictive for postdischarge stroke/death, but not for in-hospital events (Table IV).

**Predictors for other adverse events**

A history of COPD or dyspnea was predictive for postdischarge and 30-day death but not for in-hospital death. (Table V, online only) For cardiac events, no differential predictors were identified in the postdischarge time period compared with in-hospital time frame (Table VI, online only). As was seen with death and stroke/death, patients with a history of COPD were at increased risk for postdischarge and 30-day combined S/D/CE but not for in-hospital adverse events (Table VII, online only). Although the risk factors identified for

**Table III.** Independent preoperative predictors for in-hospital, postdischarge, and 30-day stroke

	<i>In-hospital</i>			<i>Postdischarge</i>			<i>30-day</i>		
	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>
Female	1.0	0.8-1.3	.9	<b>1.6</b>	<b>1.2-2.1</b>	<b>&lt;.01</b>	1.2	0.99-1.4	.06
Age <60 years <sup>a</sup>	1.2	0.9-1.7	.1	1.5	0.99-2.2	.07	<b>1.3</b>	<b>1.04-1.7</b>	<b>.03</b>
Redo CEA	<b>3.3</b>	<b>1.03-10.6</b>	<b>&lt;.05</b>	2.4	0.3-17.2	.4	<b>3.0</b>	<b>1.1-8.2</b>	<b>.04</b>
Hx of stroke/hemiplegia	<b>1.9</b>	<b>1.5-2.3</b>	<b>&lt;.001</b>	<b>2.3</b>	<b>1.7-3.1</b>	<b>&lt;.001</b>	<b>2.0</b>	<b>1.7-2.4</b>	<b>&lt;.001</b>
Hx of TIA	<b>1.4</b>	<b>1.2-1.8</b>	<b>&lt;.01</b>	<b>1.5</b>	<b>1.1-2.1</b>	<b>&lt;.01</b>	<b>1.5</b>	<b>1.2-1.7</b>	<b>&lt;.001</b>
Hx of angina/MI	<b>1.6</b>	<b>1.04-2.4</b>	<b>.03</b>	1.7	1.0-3.1	.06	<b>1.6</b>	<b>1.2-2.3</b>	<b>&lt;.01</b>
Renal failure	1.0	0.4-2.2	.9	<b>3.0</b>	<b>1.4-6.2</b>	<b>&lt;.01</b>	1.5	0.9-2.7	.1
Underweight <sup>b</sup>	<b>2.3</b>	<b>1.3-4.1</b>	<b>&lt;.01</b>	0.9	0.3-2.9	.8	<b>1.8</b>	<b>1.1-3.0</b>	<b>.03</b>
Obesity class II <sup>b</sup>	<b>1.5</b>	<b>1.01-2.1</b>	<b>&lt;.05</b>	0.9	0.5-2.0	.6	1.3	0.9-1.7	.2
Functional status, dependent <sup>c</sup>	<b>1.6</b>	<b>1.2-3.2</b>	<b>&lt;.01</b>	1.4	0.9-2.3	.2	<b>1.7</b>	<b>1.3-2.2</b>	<b>&lt;.001</b>
Emergency procedure	<b>1.9</b>	<b>1.1-3.2</b>	<b>.01</b>	0.9	0.3-2.4	.8	1.5	0.99-2.5	.05
ASA class >3	<b>1.4</b>	<b>1.1-1.8</b>	<b>.02</b>	1.2	0.8-1.7	.4	<b>1.3</b>	<b>1.1-1.6</b>	<b>.02</b>

ASA, American Society of Anesthesiology; CEA, carotid endarterectomy; CI, confidence interval; Hx, history; MI, myocardial infarction; OR, odds ratio; TIA, transient ischemic attack.

Bold values indicate  $P < .05$ .

<sup>a</sup>vs 60-70 years.

<sup>b</sup>vs normal weight.

<sup>c</sup>vs independent.

postdischarge events (but not for in-hospital outcome) predicted different endpoints, the cumulative effect of these risk factors (female sex, renal failure, and COPD) is shown in Table VIII (online only) for all different time points. Patients undergoing emergency procedures were at increased risk for all in-hospital events but not for postdischarge events. All independent predictors for death (Table V, online only), cardiac events (Table VI, online only), and combined S/D/CE (Table VII, online only) with respect to the different time intervals are available as an online supplement.

## DISCUSSION

In a large number of patients among both community and academic institutions in the United States, CEA was performed with very low complication rates for stroke, death, or cardiac events (MI or cardiac arrest). Approximately one-third of procedural-related events occur after discharge from the hospital. This was true for both patients with prior neurologic symptoms and for those who were asymptomatic. In this study, we identified predictors for postdischarge events, which have not previously been reported. We found that independent predictors for postdischarge events but not for in-hospital events were female sex (stroke and stroke/death), renal failure (stroke), and COPD (death, stroke/death, and S/D/CE).

Previously, Sidawy et al<sup>4</sup> described the occurrence of adverse events happening after discharge but within 30 days of revascularization. For CAS, they found that 31% of combined strokes/deaths or MIs were not captured during hospital admission; for CEA, 28% of events were missed when only analyzing in-hospital data. Although less than one-half of patients in that analysis had 30-day follow-up, our results confirm these estimates in a 100% follow-up cohort. Most administrative vascular registries do not include postdischarge events. The results

of this study indicate that this may be a confounding feature for many studies based on such datasets.<sup>1-3,10</sup> It is well known that hospital administrative data are not reliable to estimate nonfatal operative complication rates for surgical procedures in general.<sup>11</sup> Recently, the reliability of administrative data to determine outcomes specifically for carotid revascularization procedures was questioned.<sup>9,12</sup>

Consistent entry of data beyond the in-hospital period seems to be not only important for true perioperative event risk estimation but also to identify patients at risk for adverse perioperative events. Registries such as the NSQIP are critical to evaluate rare events such as postoperative stroke after CEA since single-surgeon or single-center experiences are typically underpowered to evaluate procedures with low event rates. Our results demonstrate that in a subgroup of patients, adverse events are more likely to happen after discharge, possibly influencing preoperative counseling and perioperative management. The timing of strokes suggests that some may be due to hyperperfusion and subsequent intracerebral hemorrhage.<sup>13,14</sup> Intracerebral hemorrhage occurs at unpredictable intervals in the postoperative course and its mechanism remains unclear. Previous analyses identified high-grade stenosis and severe intra- or postoperative hypertension as possible risk factors.<sup>13</sup> Better blood pressure control and perhaps selective transcranial Doppler monitoring might benefit these patients.<sup>15</sup> "Late" stroke might also occur due to thromboembolism<sup>13</sup> in patients who do not respond to antiplatelet therapy. Preoperative testing for antiplatelet responsiveness may identify subgroups at risk that may benefit from additional antiplatelet medication. Unfortunately, the type and laterality of postoperative stroke is not captured in the NSQIP. Future research efforts should evaluate the mechanism of postoperative stroke to guide further changes in perioperative management.

**Table IV.** Independent preoperative predictors for in-hospital, postdischarge, and 30-day stroke or death

	<i>In-hospital</i>			<i>Postdischarge</i>			<i>30-day</i>		
	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>
Female	1.1	0.9-1.3	.4	<b>1.4</b>	<b>1.1-1.7</b>	<b>&lt;.01</b>	<b>1.2</b>	<b>1.03-1.4</b>	<b>.02</b>
Age <60 years <sup>a</sup>	1.1	0.9-1.6	.2	1.4	0.96-1.9	.09	<b>1.3</b>	<b>1.01-1.6</b>	<b>&lt;.05</b>
Age >80 years <sup>a</sup>	<b>1.4</b>	<b>1.1-1.8</b>	<b>.01</b>	1.3	0.9-1.9	.09	<b>1.4</b>	<b>1.1-1.7</b>	<b>&lt;.01</b>
Hx of stroke/hemiplegia	<b>1.8</b>	<b>1.5-2.2</b>	<b>&lt;.001</b>	<b>2.0</b>	<b>1.5-2.5</b>	<b>&lt;.001</b>	<b>1.9</b>	<b>1.6-2.2</b>	<b>&lt;.001</b>
Hx of TIA	<b>1.3</b>	<b>1.04-1.5</b>	<b>.02</b>	1.3	0.99-1.6	.05	<b>1.3</b>	<b>1.1-1.5</b>	<b>&lt;.01</b>
Hx of angina/MI	<b>1.9</b>	<b>1.4-2.7</b>	<b>&lt;.001</b>	<b>1.6</b>	<b>1.1-2.6</b>	<b>.03</b>	<b>1.8</b>	<b>1.4-2.4</b>	<b>&lt;.001</b>
Renal failure	<b>2.1</b>	<b>1.3-3.4</b>	<b>&lt;.01</b>	<b>3.2</b>	<b>1.9-5.5</b>	<b>&lt;.001</b>	<b>2.5</b>	<b>1.7-3.6</b>	<b>&lt;.001</b>
Hx of COPD	1.2	0.9-1.5	.3	<b>1.8</b>	<b>1.4-2.4</b>	<b>&lt;.001</b>	<b>1.4</b>	<b>1.2-1.7</b>	<b>&lt;.01</b>
Hx of PVD	<b>1.5</b>	<b>1.1-2.0</b>	<b>&lt;.01</b>	1.3	0.9-1.9	.1	<b>1.4</b>	<b>1.2-1.8</b>	<b>&lt;.001</b>
Functional status, dependent <sup>b</sup>	<b>2.2</b>	<b>1.7-2.9</b>	<b>&lt;.001</b>	<b>1.6</b>	<b>1.2-2.4</b>	<b>&lt;.01</b>	<b>2.0</b>	<b>1.6-2.5</b>	<b>&lt;.001</b>
Emergency procedure	<b>2.7</b>	<b>1.8-3.9</b>	<b>&lt;.001</b>	0.6	0.2-1.5	.3	<b>1.9</b>	<b>1.3-2.7</b>	<b>&lt;.01</b>
ASA class >3	<b>1.6</b>	<b>1.3-2.0</b>	<b>&lt;.001</b>	1.3	0.99-1.8	.06	<b>1.5</b>	<b>1.3-1.8</b>	<b>&lt;.001</b>

ASA, American Society of Anesthesiology; CI, confidence interval; COPD, chronic obstructive pulmonary disease; Hx, history; MI, myocardial infarction; OR, odds ratio; PVD, peripheral vascular disease, TIA, transient ischemic attack.

Bold values indicate  $P < .05$ .

<sup>a</sup>vs 60-70 years.

<sup>b</sup>vs independent.

In our study, we found that stroke in women seems to happen more frequently after discharge. Studies based on in-hospital results did not find differences in stroke and death rates after CAS and CEA in relation to sex.<sup>10,16</sup> However, several others have also identified women as a subgroup of patients at higher risk for 30-day adverse outcome after CEA.<sup>6,17</sup> Especially for asymptomatic women, the benefit of surgery may be less than that for men.<sup>18,19</sup> In our analyses, the difference between men and woman in postdischarge events was identified for both those with, and without a previous neurologic event, although this did not quite reach statistical significance for asymptomatic patients. Sex differences in outcome of CEA are still not well understood and merit further investigation.<sup>20,21</sup> Renal failure was also an independent predictor for postdischarge stroke but not for in-hospital or 30-day stroke. Two studies based on NSQIP data<sup>6,22</sup> found that impaired renal function was an independent risk factor for mortality and cardiac and pulmonary morbidity after CEA, but was not associated with increased risk of neurologic complications at 30 days, which was consistent with our results. Also, other reports have suggested that renal failure is a risk factor for increased stroke risk and a marker for advanced atherosclerotic disease causing morbidity and mortality.<sup>23-25</sup>

Several authors have reported risk factors associated with adverse outcome after CEA to identify high-risk groups and optimize management of patients with carotid artery disease.<sup>5,6,18,26,27</sup> Similar to prior reports, we found that symptom status was a consistent predictor for adverse events (both in-hospital and postdischarge), and that a history of preoperative stroke was more predictive than a history of TIA.<sup>27,28</sup> Among other risk factors for only in-hospital or both in-hospital and postdischarge outcome, we identified several patient characteristics previously described by others, including diabetes<sup>26,27</sup> and age

>80 years.<sup>27,29</sup> Interestingly, we found that patients with redo CEA had increased risk for in-hospital stroke, whereas others did not<sup>30,31</sup> or only identified increased risk for local complications such as cranial nerve injury.<sup>32</sup> However, these studies might not have detected a difference because of low event rates and small sample sizes. Adequately powered studies are needed to define optimal treatment in these patients. Under- and overweight patients had an increased risk for stroke, suggesting that obesity is not only a risk factor for mortality<sup>33,34</sup> but also for morbidity after CEA. This obesity paradox has been previously identified with vascular surgery procedures with a reverse J-shaped relation of BMI and adverse outcome, with the highest risk in the underweight and morbidly obese extremes, and the lowest rates in the overweight and mildly obese patients.<sup>33-36</sup> Not surprisingly and consistent with previous literature,<sup>5,27,37</sup> emergent procedures were predictive for all in-hospital adverse outcomes. This increased risk was, however, not persistent after discharge. This is understandable, as most emergent procedures would be presumed to be performed for either stroke-in-evolution or crescendo TIA.<sup>28,38</sup>

This study has several limitations. NSQIP does not define preoperative symptom status in the same manner as most clinical trials.<sup>6</sup> Although a recent report from our group showed that NSQIP does identify symptomatic patients with a high sensitivity, the number of false-positives was about 25% (because of stroke or TIA occurring >6 months prior to surgery or contralateral to the CEA).<sup>9</sup> Therefore, we were only able to stratify the analysis regarding timing of events for patients with and without a previous neurologic event and accounted for these symptoms individually in multivariable prediction models. However, importantly, we did not find a difference in the occurrence of postdischarge stroke in those who were clearly asymptomatic compared with a group who had

preoperative neurologic events, the vast majority of which were likely within 6 months of and ipsilateral to their CEA. Another limitation inherent to this database is the lack of anatomical preoperative factors such as history of previous neck radiation, degree of stenosis, or radical neck dissection. Also, the retrospective nature of the data may introduce a selection bias, which might have influenced the results. Because nonfatal cardiac events proved to have a strong effect on patient survival, we included cardiac events as one of our primary outcome measures. Our definition of a cardiac event will capture both cardiac arrest and new Q-wave MI on electrocardiogram but is somewhat limited by the NSQIP database because patients with ST-elevation MI (troponin leak) will be missed. Lastly, CAS procedures are not yet included in the NSQIP but will be in the future allowing comparison of the two procedures.

## CONCLUSIONS

With 38% of perioperative adverse events after CEA happening posthospitalization, regardless of symptom status, surgeons should be alert to the ongoing risks after discharge particularly in women and patients with renal failure or a history of COPD. For research and quality improvement purposes, the full 30-day adverse event rates should be reported and compared when evaluating CEA or comparing CAS and CEA.

## AUTHOR CONTRIBUTIONS

Conception and design: MF, RB, RL, AH, MW, FM, GJB, MS

Analysis and interpretation: MF, RB, AH, GJB, MS

Data collection: MF, RB, RB, GJB, MS

Writing the article: MF, RB, GJB, MS

Critical revision of the article: MF, RB, RL, AH, MW, FM, GJB, MS

Final approval of the article: MF, RB, RL, AH, MW, FM, GJB, MS

Statistical analysis: MF, RB, RL, MS

Obtained funding: Not applicable

Overall responsibility: MS

## REFERENCES

- Nolan BW, De Martino RR, Goodney PP, Schanzer A, Stone DH, Butzel D, et al. Comparison of carotid endarterectomy and stenting in real world practice using a regional quality improvement registry. *J Vasc Surg* 2012;56:990-6.
- Eslami MH, McPhee JT, Simons JP, Schanzer A, Messina LM. National trends in utilization and postprocedure outcomes for carotid artery revascularization 2005 to 2007. *J Vasc Surg* 2011;53:307-15.
- Vogel TR, Dombrovskiy VY, Haser PB, Scheirer JC, Graham AM. Outcomes of carotid artery stenting and endarterectomy in the United States. *J Vasc Surg* 2009;49:325-30.
- Sidawy AN, Zwolak RM, White RA, Siami FS, Schermerhorn ML, Sicard GA. Risk-adjusted 30-day outcomes of carotid stenting and endarterectomy: results from the SVS Vascular Registry. *J Vasc Surg* 2009;49:71-9.
- Goodney PP, Likosky DS, Cronenwett JL. Factors associated with stroke or death after carotid endarterectomy in Northern New England. *J Vasc Surg* 2008;48:1139-45.
- Kang JL, Chung TK, Lancaster RT, Lamuraglia GM, Conrad MF, Cambria RP. Outcomes after carotid endarterectomy: is there a high-risk population? A National Surgical Quality Improvement Program report. *J Vasc Surg* 2009;49:331-8.
- Fink AS, Campbell DA Jr, Mentzer RM Jr, Henderson WG, Daley J, Bannister J, et al. The National Surgical Quality Improvement Program in non-veterans administration hospitals: initial demonstration of feasibility. *Ann Surg* 2002;236:344-53.
- Shiloach M, Frencher SK Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh MG, et al. Toward robust information: data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. *J Am Coll Surg* 2009;210:6-16.
- Bensley RP, Yoshida S, Lo RC, Fokkema M, Hamdan AD, Wyers MC, et al. Accuracy of administrative data versus clinical data to evaluate carotid endarterectomy and carotid stenting [published online ahead of print March 9, 2013]. *J Vasc Surg* doi: 10.1016/j.jvs.2013.01.010.
- Rockman CB, Garg K, Jacobowitz GR, Berger JS, Mussa FF, Cayne NS, et al. Outcome of carotid artery interventions among female patients, 2004 to 2005. *J Vasc Surg* 2011;53:1457-64.
- Best WR, Khuri SF, Phelan M, Hur K, Henderson WG, Demakis JG, et al. Identifying patient preoperative risk factors and postoperative adverse events in administrative databases: results from the department of veterans affairs national surgical quality improvement program. *J Am Coll Surg* 2002;194:257-66.
- Hertzer NR. The Nationwide Inpatient Sample may contain inaccurate data for carotid endarterectomy and carotid stenting. *J Vasc Surg* 2011;55:263-6.
- Riles TS, Imparato AM, Jacobowitz GR, Lamparello PJ, Giangola G, Adelman MA, et al. The cause of perioperative stroke after carotid endarterectomy. *J Vasc Surg* 1994;19:206-16.
- de Borst GJ, Moll FL, van de Pavoordt HD, Mauser HW, Kelder JC, Ackerstaff RG. Stroke from carotid endarterectomy: when and how to reduce perioperative stroke rate? *Eur J Vasc Endovasc Surg* 2001;21:484-9.
- Pennekamp CW, Tromp SC, Ackerstaff RG, Bots ML, Immink RV, Spiering W, et al. Prediction of cerebral hyperperfusion after carotid endarterectomy with transcranial Doppler. *Eur J Vasc Endovasc Surg* 2012;43:371-6.
- Akbari CM, Pulling MC, Pomposelli FB Jr, Gibbons GW, Campbell DR, LoGerfo FW. Gender and carotid endarterectomy: does it matter? *J Vasc Surg* 2000;31:1103-9.
- Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet* 2004;363:915-24.
- Calvillo-King L, Xuan L, Zhang S, Tuhim S, Halm EA. Predicting risk of perioperative death and stroke after carotid endarterectomy in asymptomatic patients. *Stroke* 2010;41:2786-94.
- Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis. *Stroke* 2004;35:2425-7.
- den Hartog AG, Algra A, Moll FL, de Borst GJ. Mechanisms of gender-related outcome differences after carotid endarterectomy. *J Vasc Surg* 2010;52:1062-71.e6.
- Bensley RP, Lo RC, Hurks R, Chaikof EL, Hamdan AD, Wyers MC, et al. Gender differences in presentation of patients undergoing CEA and CAS in VSGNE. Manuscript in progress; 2013.
- Sidawy AN, Aidinian G, Johnson Iii ON, White PW, DeZee KJ, Henderson WG. Effect of chronic renal insufficiency on outcomes of carotid endarterectomy. *J Vasc Surg* 2008;48:1423-30.
- Kretz B, Abello N, Brenot R, Steinmetz E. The impact of renal insufficiency on the outcome of carotid surgery is influenced by the definition used. *J Vasc Surg* 2010;51:43-50.
- Hamdan AD, Pomposelli FB Jr, Gibbons GW, Campbell DR, LoGerfo FW. Renal insufficiency and altered postoperative risk in carotid endarterectomy. *J Vasc Surg* 1999;29:1006-11.
- Stoner MC, Abbott WM, Wong DR, Hua HT, Lamuraglia GM, Kwolek CJ, et al. Defining the high-risk patient for carotid

- endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database. *J Vasc Surg* 2006;43:285-95.
26. Tu JV, Wang H, Bowyer B, Green L, Fang J, Kucey D, et al. Risk factors for death or stroke after carotid endarterectomy. *Stroke* 2003;34:2568-73.
  27. Halm EA, Tuhim S, Wang JJ, Rockman C, Riles TS, Chassin MR. Risk factors for perioperative death and stroke after carotid endarterectomy. *Stroke* 2009;40:221-9.
  28. Bond R, Rerkasem K, Rothwell PM. Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. *Stroke* 2003;34:2290-301.
  29. Voeks JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC, et al. Age and outcomes after carotid stenting and endarterectomy. *Stroke* 2011;42:3484-90.
  30. de Borst GJ, Zanen P, de Vries J-PP, van de Pavoordt ED, Ackerstaff RG, Moll FL. Durability of surgery for restenosis after carotid endarterectomy. *J Vasc Surg* 2008;47:363-71.
  31. Hobson RW 2nd, Goldstein JE, Jamil Z, Lee BC, Padberg FT Jr, Hanna AK, et al. Carotid restenosis: operative and endovascular management. *J Vasc Surg* 1999;29:228-35; discussion: 235-8.
  32. AbuRahma AF, Abu-Halimah S, Bensenhaver J, Nanjundappa A, Stone PA, Dean LS, et al. Primary carotid artery stenting versus carotid artery stenting for postcarotid endarterectomy stenosis. *J Vasc Surg* 2009;50:1031-9.
  33. Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. *J Vasc Surg* 2009;49:140-7.e1.
  34. Mullen JT, Moorman DW, Davenport DL. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. *Ann Surg* 2009;250:166-72.
  35. Reeves JG, Kasirajan K, Veeraswamy RK, Ricotta Ii JJ, Salam AA, Dodson TF, et al. Characterization of resident surgeon participation during carotid endarterectomy and impact on perioperative outcomes. *J Vasc Surg* 2011;55:268-73.
  36. Giles KA, Wyers MC, Pomposelli FB, Hamdan AD, Ching YA, Schermerhorn ML. The impact of body mass index on perioperative outcomes of open and endovascular abdominal aortic aneurysm repair from the National Surgical Quality Improvement Program, 2005-2007. *J Vasc Surg* 2010;52:1471-7.
  37. Musser DJ, Nicholas GG, Reed JF III. Death and adverse cardiac events after carotid endarterectomy. *J Vasc Surg* 1994;19:615-22.
  38. Rerkasem K, Rothwell PM. Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery. *Stroke* 2009;40:e564-72.

Submitted Sep 6, 2012; accepted Nov 17, 2012.

*Additional material for this article may be found online at [www.jvascsurg.org](http://www.jvascsurg.org).*



**Appendix (online only).** Definitions of preoperative variables.

<i>Variable</i>	<i>Definition</i>
Hx of stroke/hemiplegia	A history of a cerebrovascular accident (embolic, thrombotic, or hemorrhagic) with or without persistent residual motor, sensory, or cognitive dysfunction. Acute or chronic neuromuscular injury resulting in total or partial paralysis or paresis (weakness) of one side of the body.
Hx of TIA	A history of focal neurologic deficits (eg, numbness of an arm or amaurosis fugax) of sudden onset and brief duration (usually <30 minutes) that usually reflects dysfunction in a cerebral vascular distribution.
Hx of angina or MI	A history of angina (pain or discomfort between the diaphragm and the mandible resulting from myocardial ischemia) or myocardial infarction (MI, a non-Q wave or a Q wave infarct in the six months prior to surgery) For patients on anti-anginal medications, only patients who had angina within one month prior to surgery are included.
CHF	Newly diagnosed CHF within the previous 30 days or a diagnosis of chronic CHF with new signs or symptoms in the 30 days prior to surgery
Previous PCI	A PCI at any time (including any attempted PCI). This includes either balloon dilatation or stent placement.
Previous cardiac surgery	Any major cardiac surgical procedures, includes coronary artery bypass graft surgery, valve replacement or repair, repair of atrial or ventricular septal defects, great thoracic vessel repair, cardiac transplant, left ventricular aneurysmectomy, insertion of LVADs, etc. Not include are pacemaker insertions or AICD insertions.
Diabetes mellitus	Diabetes mellitus with oral agents or insulin. The treatment regimen of the patient's chronic, long-term management.
Hypertension	Persistent elevation of systolic blood pressure > 140 mm Hg or a diastolic blood pressure > 90 mm Hg or requires an antihypertensive treatment (eg, diuretics, beta blockers, ACE inhibitors, calcium channel blockers) at the time the patient is being considered as a candidate for surgery (which should be no longer than 30 days prior to surgery).
Current smoker	Current smoker (cigarettes) within 1 year.
Hx of smoking	If the patient has ever been a smoker, the total number of pack/years (number of packs of cigarettes smoked per day times the number of years the patient has smoked) of smoking for this patient is provided.
Alcohol use > 2 drinks/day	The patient admits to drinking >2 oz of hard liquor or > two 12 oz cans of beer or > two 6 oz glasses of wine per day in the two weeks prior to admission.
BMI	BMI, calculated as weight (kg) divided by height (m <sup>2</sup> ) <18.5 underweight, 18.5-24.9 normal weight, 25-29.9 overweight, 30-34.9 obese class I, 35-40 obese class II, ≥40 obese class III
Renal failure	Acute (steadily increasing azotemia [increase in BUN] and a rising creatinine of above 3 mg/dL < 24 hours prior to surgery) or chronic renal failure requiring treatment with peritoneal dialysis, hemodialysis, hemofiltration, hemodiafiltration, or ultrafiltration within 2 weeks prior to surgery.
Hx of COPD	History of severe chronic obstructive pulmonary disease resulting in any one or more of the following: <ul style="list-style-type: none"> <li>- Functional disability from COPD (eg, dyspnea, inability to perform ADLs)</li> <li>- Hospitalization in the past for treatment of COPD</li> <li>- Requires chronic bronchodilator therapy with oral or inhaled agents.</li> <li>- An FEV1 of &lt;75% of predicted on pulmonary function testing.</li> </ul> Patients are not included whose only pulmonary disease is asthma, an acute and chronic inflammatory disease of the airways resulting in bronchospasm. Patients are not included with diffuse interstitial fibrosis or sarcoidosis.
Dyspnea	Difficult, painful, or labored breathing <30 days of surgery. Dyspnea may be symptomatic of numerous disorders that interfere with adequate ventilation or perfusion of the blood with oxygen
Steroid use	If a patient requires regular administration of oral or parenteral corticosteroid medications (eg, Prednisone, Decadron) in the 30 days prior to surgery for a chronic medical condition (eg, COPD, asthma, rheumatologic disease, rheumatoid arthritis, inflammatory bowel disease). Patients who only receive short course steroids (duration 10 days or less) in the 30 days prior to surgery are not included
Hx of revascularization for PVD	History of revascularization/amputation for PVD: any type of angioplasty (including stent placement) or revascularization procedure for atherosclerotic PVD (eg, aorta-femoral, femoral-femoral, femoral-popliteal) or a patient who has had any type of amputation procedure for PVD (eg, toe amputations, transmetatarsal amputations, below the knee or above the knee amputations). Patients who have had amputation for trauma or a resection of abdominal aortic aneurysms should not be included.

Appendix (online only). Continued.

Variable	Definition
Restpain/gangrene	Rest pain is a more severe form of ischemic pain due to occlusive disease, which occurs at rest and is manifested as a severe, unrelenting pain aggravated by elevation and often preventing sleep. Gangrene is a marked skin discoloration and disruption indicative of death and decay of tissues in the extremities due to severe and prolonged ischemia. Patients included with ischemic ulceration and/or tissue loss related to peripheral vascular disease. Fournier's gangrene are not included.
Functional status	Functional health status prior to surgery <30 days. This variable focuses on the patient's abilities to perform activities of daily living.
Emergency procedure	An emergency case is usually performed as soon as possible and no later than 12 hours after the patient has been admitted to the hospital or after the onset of related preoperative symptomatology.
ASA class > 3	The ASA Physical Status Classification of the patient's present physical condition on a scale from 1-5 as it appears on the anesthesia record. ASA 1 - Normal healthy patient ASA 2 - Patient with mild systemic disease ASA 3 - Patient with severe systemic disease ASA 4 - Patient with severe systemic disease that is a constant threat to life ASA 5 - Moribund patient who is not expected to survive without the operation.

ACE, Angiotensin-converting-enzyme; AICD, automatic implantable cardioverter defibrillator; ASA, American Society of Anesthesiologists; ADLs, Activities of daily living; BMI, body mass index; BUN, blood urea nitrogen; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; Hx, history; LVADs, left ventricular assist devices; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TIA, transient ischemic attack.

Table V (online only). Independent preoperative predictors for in-hospital, postdischarge, and 30-day death

	In-hospital			Postdischarge			30-day		
	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
Female	1.1	0.8-1.6	.7	1.2	0.8-1.7	.3	1.1	0.9-1.5	.3
Age >80 years <sup>a</sup>	<b>2.5</b>	<b>1.5-4.2</b>	<b>&lt;.001</b>	<b>2.4</b>	<b>1.5-3.8</b>	<b>&lt;.001</b>	<b>2.4</b>	<b>1.7-3.5</b>	<b>&lt;.001</b>
Hx of stroke/hemiplegia	<b>1.7</b>	<b>1.1-2.5</b>	<b>.01</b>	<b>1.7</b>	<b>1.2-2.5</b>	<b>&lt;.01</b>	<b>1.7</b>	<b>1.3-2.2</b>	<b>&lt;.001</b>
Hx of angina/MI	<b>2.8</b>	<b>1.6-4.7</b>	<b>&lt;.001</b>	1.1	0.5-2.2	.8	<b>1.9</b>	<b>1.2-2.9</b>	<b>&lt;.01</b>
Renal failure	<b>5.7</b>	<b>3.1-10.3</b>	<b>&lt;.001</b>	<b>3.0</b>	<b>1.4-6.4</b>	<b>&lt;.01</b>	<b>4.3</b>	<b>2.7-6.9</b>	<b>&lt;.001</b>
Hx of CHF	1.7	0.8-3.6	.2	2.0	0.9-4.5	.1	<b>1.9</b>	<b>1.02-3.2</b>	<b>.04</b>
Dyspnea	1.3	0.9-2.1	.2	<b>1.7</b>	<b>1.1-2.5</b>	<b>&lt;.01</b>	<b>1.5</b>	<b>1.2-2.0</b>	<b>&lt;.01</b>
Hx of COPD	1.4	0.9-2.3	.1	<b>2.5</b>	<b>1.6-3.7</b>	<b>&lt;.001</b>	<b>1.9</b>	<b>1.4-2.6</b>	<b>&lt;.001</b>
Hx of PVD	<b>1.9</b>	<b>1.1-3.0</b>	<b>.01</b>	<b>1.8</b>	<b>1.2-2.8</b>	<b>.01</b>	<b>1.8</b>	<b>1.3-2.5</b>	<b>&lt;.001</b>
Functional status, dependent <sup>b</sup>	<b>3.6</b>	<b>2.4-5.6</b>	<b>&lt;.001</b>	<b>2.0</b>	<b>1.2-3.3</b>	<b>&lt;.01</b>	<b>2.8</b>	<b>2.0-3.8</b>	<b>&lt;.001</b>
Emergency procedure	<b>5.4</b>	<b>3.0-9.5</b>	<b>&lt;.001</b>	0.4	0.1-2.5	.3	<b>2.9</b>	<b>1.7-4.8</b>	<b>&lt;.001</b>
ASA class >3	<b>2.8</b>	<b>1.8-4.1</b>	<b>&lt;.001</b>	<b>1.4</b>	<b>0.9-2.1</b>	<b>&lt;.01</b>	<b>1.9</b>	<b>1.4-2.5</b>	<b>&lt;.001</b>

ASA, American Society of Anesthesiology; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; Hx, history; MI, myocardial infarction; OR, odds ratio; PVD, peripheral vascular disease, TIA, transient ischemic attack.

Bold values indicate  $P < .05$ .

<sup>a</sup>vs 60-70 years.

<sup>b</sup>vs independent.

**Table VI (online only).** Independent preoperative predictors for in-hospital, postdischarge, and 30-day cardiac events

	<i>In-hospital</i>			<i>Postdischarge</i>			<i>30-day</i>		
	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>
Female	1.1	0.8-1.4	.5	0.9	0.6-1.4	.7	1.0	0.8-1.3	.7
Race non-white <sup>a</sup>	<b>1.6</b>	<b>1.1-2.4</b>	<b>.01</b>	1.2	0.6-2.2	.6	<b>1.5</b>	<b>1.1-2.1</b>	<b>.02</b>
Age >80 years <sup>b</sup>	<b>2.7</b>	<b>1.8-3.8</b>	<b>&lt;.001</b>	<b>2.0</b>	<b>1.2-3.3</b>	<b>&lt;.01</b>	<b>2.4</b>	<b>1.8-3.3</b>	<b>&lt;.001</b>
Hx of stroke/hemiplegia	<b>1.5</b>	<b>1.1-2.0</b>	<b>&lt;.01</b>	1.2	0.8-1.8	.3	<b>1.4</b>	<b>1.1-1.8</b>	<b>&lt;.01</b>
Hx of angina/MI	<b>3.4</b>	<b>2.3-5.0</b>	<b>&lt;.001</b>	1.9	0.9-3.6	.07	<b>2.8</b>	<b>2.0-4.0</b>	<b>&lt;.001</b>
Diabetes	1.7	1.3-2.3	<b>&lt;.001</b>	1.2	0.8-1.8	.4	<b>1.5</b>	<b>1.2-1.9</b>	<b>&lt;.001</b>
Renal failure	<b>2.1</b>	<b>1.1-4.1</b>	<b>.03</b>	<b>2.7</b>	<b>1.2-6.4</b>	<b>.02</b>	<b>2.3</b>	<b>1.3-3.9</b>	<b>&lt;.01</b>
Dyspnea	<b>1.4</b>	<b>1.04-1.9</b>	<b>.02</b>	<b>1.6</b>	<b>1.02-2.4</b>	<b>.04</b>	<b>1.5</b>	<b>1.1-1.9</b>	<b>&lt;.01</b>
Hx of PVD	<b>1.8</b>	<b>1.3-2.5</b>	<b>&lt;.01</b>	1.6	0.97-2.7	.07	<b>1.7</b>	<b>1.3-2.3</b>	<b>&lt;.001</b>
ASA >3	<b>1.6</b>	<b>1.2-2.2</b>	<b>&lt;.01</b>	<b>2.2</b>	<b>1.4-3.3</b>	<b>&lt;.001</b>	<b>1.8</b>	<b>1.4-2.3</b>	<b>&lt;.001</b>
Emergency	<b>2.5</b>	<b>1.4-4.7</b>	<b>&lt;.01</b>	0.9	0.2-3.7	.9	<b>2.0</b>	<b>1.1-3.5</b>	<b>.02</b>

ASA, American Society of Anesthesiology; *CI*, confidence interval; *Hx*, history; *MI*, myocardial infarction; *OR*, odds ratio; *PVD*, peripheral vascular disease. Adjusted for sex.

Bold values indicate  $P < .05$ .

<sup>a</sup>vs white.

<sup>b</sup>vs 60-70 years.

**Table VII (online only).** Independent preoperative predictors for in-hospital, postdischarge, and 30-day stroke, death, or cardiac events

	<i>In-hospital</i>			<i>Postdischarge</i>			<i>30-day</i>		
	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>	<i>OR</i>	<i>95% CI</i>	<i>P value</i>
Female	1.1	0.9-1.3	.2	1.2	0.97-1.5	.08	<b>1.1</b>	<b>1.01-1.3</b>	<b>&lt;.05</b>
Age >80 years <sup>a</sup>	<b>1.7</b>	<b>1.3-2.1</b>	<b>&lt;.001</b>	<b>1.6</b>	<b>1.2-2.1</b>	<b>&lt;.01</b>	<b>1.6</b>	<b>1.4-2.0</b>	<b>&lt;.001</b>
Redo CEA	<b>3.2</b>	<b>1.3-8.0</b>	<b>.02</b>	1.2	0.2-8.5	.9	<b>2.4</b>	<b>1.04-5.7</b>	<b>.04</b>
Hx of stroke/hemiplegia	<b>1.7</b>	<b>1.4-2.0</b>	<b>&lt;.001</b>	<b>1.7</b>	<b>1.4-2.2</b>	<b>&lt;.001</b>	<b>1.7</b>	<b>1.5-1.9</b>	<b>&lt;.001</b>
Hx of TIA	1.2	0.9-1.4	.06	<b>1.3</b>	<b>1.01-1.6</b>	<b>.04</b>	1.2	1.1-1.4	<b>&lt;.01</b>
Diabetes	1.2	<b>1.03-1.4</b>	<b>.02</b>	1.0	0.8-1.3	.7	1.2	<b>1.01-1.3</b>	<b>.04</b>
Hx of angina/MI	<b>2.3</b>	<b>1.8-3.0</b>	<b>&lt;.001</b>	<b>1.7</b>	<b>1.2-2.6</b>	<b>&lt;.01</b>	<b>2.1</b>	<b>1.7-2.6</b>	<b>&lt;.001</b>
Renal failure	<b>1.8</b>	<b>1.2-2.9</b>	<b>&lt;.01</b>	<b>3.0</b>	<b>1.8-5.0</b>	<b>&lt;.001</b>	<b>2.5</b>	<b>1.7-3.6</b>	<b>&lt;.001</b>
Hx of COPD	1.1	0.9-1.4	.4	<b>1.8</b>	<b>1.4-2.3</b>	<b>&lt;.001</b>	<b>1.3</b>	<b>1.1-1.6</b>	<b>&lt;.01</b>
Hx of PVD	<b>1.5</b>	<b>1.2-1.9</b>	<b>&lt;.01</b>	1.3	0.98-1.8	.06	<b>1.4</b>	<b>1.2-1.7</b>	<b>&lt;.001</b>
Functional status, dependent <sup>b</sup>	<b>1.9</b>	<b>1.5-2.4</b>	<b>&lt;.001</b>	<b>1.6</b>	<b>1.1-2.2</b>	<b>&lt;.01</b>	<b>1.8</b>	<b>1.3-2.5</b>	<b>&lt;.001</b>
Emergency procedure	<b>2.5</b>	<b>1.8-3.6</b>	<b>&lt;.001</b>	0.6	0.2-1.5	.3	<b>1.8</b>	<b>1.3-2.5</b>	<b>&lt;.001</b>
ASA class >3	<b>1.5</b>	<b>1.3-1.9</b>	<b>&lt;.001</b>	<b>1.5</b>	<b>1.2-1.9</b>	<b>&lt;.01</b>	<b>1.5</b>	<b>1.3-1.8</b>	<b>&lt;.001</b>

ASA, American Society of Anesthesiology; *CEA*, carotid endarterectomy; *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *Hx*, history; *MI*, myocardial infarction; *OR*, odds ratio; *PVD*, peripheral vascular disease, *TIA*, transient ischemic attack.

Bold values indicate  $P < .05$ .

<sup>a</sup>vs 60-70 years.

<sup>b</sup>vs independent.

**Table VIII (online only).** Cumulative risk for stroke and stroke or death in the high-risk groups (female sex, renal failure, and COPD)<sup>a</sup> for postdischarge events

<i>Number of risk factors</i>	<i>Stroke</i>			<i>Stroke/death</i>		
	<i>In-hospital</i>	<i>Postdischarge</i>	<i>30-day</i>	<i>In-hospital</i>	<i>Postdischarge</i>	<i>30-day</i>
0	1.0%	0.4%	1.4%	1.2%	0.7%	1.8%
1	1.2%	0.7%	1.9%	1.5%	1.1%	2.6%
2	0%	2.5%	2.5%	3.5%	5.0%	8.5%
3 <sup>b</sup>	0%	0%	0%	4.3%	4.3%	8.7%

*COPD*, Chronic obstructive pulmonary disease.

Bold values indicate  $P < .05$ .

<sup>a</sup>High-risk group based on the independent predictors identified for postdischarge events by multivariable models.

<sup>b</sup>Twenty-three patients with all three risk factors present.